Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399859 | 0.83 | L3MBTL1 (0.36) | L3MBTL1ADORA2AIKBKBIDO1GAA | |
| SCHEMBL20400242 | 0.81 | L3MBTL1 (0.35) | L3MBTL1ADORA2AIKBKB | |
| SCHEMBL16848682 | 0.78 | L3MBTL1 (0.38) | L3MBTL1ADORA2AIKBKBIDO1 | |
| SCHEMBL2182410 | 0.78 | CSNK1E (0.36) | — | |
| SCHEMBL14329220 | 0.72 | ADORA2A (0.48) | ADORA2ALMNAGAA | |
| SCHEMBL15667362 | 0.71 | CDK8 (0.38) | IDO1 | |
| SCHEMBL20600838 | 0.71 | CCNE1 (0.33) | L3MBTL1ADORA2A | |
| SCHEMBL31484412 | 0.69 | L3MBTL1 (0.37) | L3MBTL1ADORA2AIKBKBIDO1 | |
| SCHEMBL11001721 | 0.69 | CYP1A2 (0.38) | L3MBTL1ADORA2AIDO1 | |
| SCHEMBL2447847 | 0.69 | PDE10A (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN4 | L3MBTL1 4670/4885ADORA2A 3196/4885IKBKB 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.